Dihydroisoindolo[2,1-a]quinazoline-5,11-dione derivatives as potent and selective inhibitors targeting hepatitis B virus

Authors

  • Jun-Fei Zhang Department of Infectious Disease, 105th Hospital, Affiliated with Anhui Medical University, Hefei, 230031
  • Bo Liu Department of Infectious Disease, 105th Hospital, Affiliated with Anhui Medical University, Hefei, 230031
  • Cong-Xin Chen Department of Infectious Disease, 105th Hospital, Affiliated with Anhui Medical University, Hefei, 230031

DOI:

https://doi.org/10.3329/bjp.v10i3.23264

Keywords:

Anti-HBV, Dihydroisoindolo[2, 1-a]quinazoline-5, 11-dione, HBV DNA replication, Lamivudine

Abstract

The construction of dihydroisoindolo[2,1-a]quinazoline-5,11-dione derivatives (4a4m), by  the condensation isatoic anhydride, appropriate amines and 2-formylbenzoic acid by using silica sulfuric acid as catalyst was reported. These dihydroisoindolo[2,1-a]quinazoline-5,11-dione derivatives (DIQ) were identified as potent inhibitors of HBV capsid assembly. The newly synthesized dihydroisoindolo[2,1-a]quinazoline-5,11-dione derivatives 4a-4m were characterized by 1H NMR, 13C NMR, and Mass spectrum and evaluated for their anti-HBV activity. Majority of the synthesized compounds inhibited the expression of viral antigens at low concentration. But five compounds, 4a, 4b, 4c, 4f, and 4m were shown potent inhibition of HBV DNA replication at submicromolar range. Of these compounds, compound 4a was the most active when compared with lamivudine.

 

 

Downloads

Download data is not yet available.
Abstract
204
Download
199

References

Arnesto D, Horspool WM, Martin N, Ramos A, Seaone C. Synthesis of cyclobutenes by the novel photochemical ring contraction of 4-substituted 2-amino-3,5-dicyano-6-phenyl-4H-pyrans. J Org Chem. 1989; 54: 3069-72.

Bonsignore L, Loy G, Secci D, Calignano A. Synthesis and pharmacological activity of 2-oxo-(2H) 1-benzopyran-3-carboxamide derivatives. Eur J Med Chem. 1993; 28: 517-20.

Breiner B, Schlatterer JC, Kovalenko SV, Greenbaum NL, Alabugin IV. DNA damage-site recognition by lysine conjugates. Proc Natl Acad Sci USA. 2007; 104: 13016-21.

Breiner B, Schlatterer JC, Kovalenko SV, Greenbaum NL, Alabugin IV. Protected 32P-Labels in Deoxyribonucleotides: Investigation of sequence selectivity of DNA photocleavage by enediyne, fulvene, and acetylenelysine conjugates. Angew Chem Int Ed. 2006; 45: 3666-70.

Dény P, Zoulim F. Hepatitis B virus: From diagnosis to treatment. Pathol Biol. 2010; 58: 245-53.

Ellis GP. In: The chemistry of heterocyclic compounds: Chro-menes, chromanes and chromones. Weissberger A, Taylor EC (eds). New York, John Wiley, 1977, p 11.

Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G. Long-term follow-up of anti-HBe positive chronic active hepatitis B. Hepatology 1998; 8; 1651-54.

Foye WO. Principidi chemico farmaceutica; Piccin, Padora, Italy, 1991, p 416.

Furumi K, Fujioka T, Fujii H, Okabe H, Nakano Y, Matsunaga H, Katano M, Mori M, Mihashi K. Novel antiproliferative falcarindiol furanocoumarin ethers from the root of Angelica japonica. Bioorg Med Chem Lett. 1998; 8: 93-96.

Hyodo S, Fujita K, Kasuyaa O, Takahashia I, Uzawab J, Koshino H. Structures of phospholipase A2 inhibitors, ergo-philones A and B. Tetrahedron 1995; 51: 6717-24.

Kortylewicz ZP, Nearman J, Baranowska-Kortylewicz J. Radiolabeled 5-Iodo-3?-O-(17?-succinyl-5?-androstan-3-one)-2?-deoxyuridine and Its 5?-monophosphate for imaging and therapy of androgen receptor-positive cancers: Synthesis and biological evaluation. J Med Chem. 2009; 52; 5124-43.

Kovalenko SV, Alabugin IV. Lysineenediyne conjugates as photochemically triggered DNA double-strand cleavage agents. Chem Commun. 2005; 1444-46.

Korba BE, Gerin JL. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 1992; 19: 55-70.

Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44; 422-31.

Oaksmith JM, Ganem B. Synthesis of a COMCestradiol conjugate for targeted, tissue-selective cancer chemotherapy. Tetrahedron Lett. 2009; 50; 3497-98.

Sato K, Mori M. Current and novel therapies for hepatitis B virus infection. Mini Rev Med Chem. 2010; 10; 20-31.

Siva Kumar K, Mahesh Kumar P, Anil Kumar K, Sreenivasulu M, Ahamed AJ, Rambabu D, Rama Krishna G, Malla Reddy C, Ravikumar K, Shivakumar K, Krishna Priya K, Kishore VLP, Pal M. A new three-component reaction: Green synthesis of novel isoindolo[2,1-a]quinazoline derivatives as potent inhibitors of TNF-?. Chem Commun. 2011; 47; 5010-12.

Stray SJ, Bourne CR, Punna S, Lewis WG, Finn MG, Zlotnick A. A heteroaryl dihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA. 2005; 102: 8138-43.

Vasilevsky SF, Govdi AI, Sorokina IV, Tolstikova TG, Baev DS, Tolstikov, GA, Mamatuyk, VI, Alabugin IV. Rapid access to new bioconjugates of betulonic acid via click chemistry. Bioorg Med Chem Lett. 2011; 21: 62-65.

Wong DKH, Cheung AM, Orourke K, Naylor CD, Detsky AS. Effect of alpha-interferon treatment in patients with heap-titis B e antigen-positive chronic hepatitis B: A meta-analysis. Ann Intern Med. 1993; 119: 312-23.

Yang WY, Breiner B, Kovalenko SV, Ben C.; Singh M, Le Grand SN, Sang QX, Strouse GF, Copland JA, Alabugin IV. C-Lysine conjugates: pH-controlled light-activated reagents for efficient double-stranded DNA cleavage with implica-tions for cancer therapy. J Am Chem Soc. 2009; 131; 11458-70.

Yang WY, Marrone SA, Minors N, Zorio DAR, Alabugin IV. Fine-tuning alkyne cyclo additions: Insights into photochemistry responsible for the double-strand DNA cleavage via structural perturbations in diaryl alkyne conjugates. Beilstein J Org Chem. 2011; 7; 813-23.

Downloads

Published

2015-07-11

How to Cite

Zhang, J.-F., B. Liu, and C.-X. Chen. “Dihydroisoindolo[2,1-a]quinazoline-5,11-Dione Derivatives As Potent and Selective Inhibitors Targeting Hepatitis B Virus”. Bangladesh Journal of Pharmacology, vol. 10, no. 3, July 2015, pp. 612-20, doi:10.3329/bjp.v10i3.23264.

Issue

Vol. 10 No. 3 (2015)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).